AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ENGN · NASDAQ · Biotechnology

enGene Therapeutics (ENGN)

Develops non-viral genetic medicines led by a bladder-cancer therapy candidate.

$2.00

vs last close−0.05 (−2.44%)

In millions of USD, except per-share figures

In millions	Q4 FY23Oct 2023	Q1 FY24Jan 2024	Q2 FY24Apr 2024	Q3 FY24Jul 2024	Q4 FY24Oct 2024	Q1 FY25Jan 2025	Q2 FY25Apr 2025	Q3 FY25Jul 2025	Q4 FY25Oct 2025	Q1 FY26Jan 2026	Q2 FY26Apr 2026	Q3 FY26Jul 2026
Cost of revenue	0	0	0	0	0	0	0	0	0	0	0	0
Gross profit	0	0	0	0	0	0	0	0	0	0	0	0
	10	11	17	17	17	27	27	30	39	31	32	34
Research & development	6	6	10	12	11	20	20	23	32	22	22	20
	4	4	6	5	8	7	6	7	10	9	10	14
General & administrative	4	4	6	5	8	7	6	7	10	9	10	14
Other expenses	0	2	1	1	−2	−53	1	1	−2	0	0	0
Operating income	−10	−11	−17	−17	−17	−27	−27	−30	−39	−31	32	34
	−72	0	2	3	2	2	2	1	1	1	−2	−2
Interest income	0	1	3	3	3	3	2	2	2	3	−3	2
Interest expense	1	1	1	1	1	1	1	1	1	1	1	1
Other non-operating income	71	−1	−3	−3	−3	−3	−2	−2	−2	−2	64	68
Income before tax	−82	−11	−15	−14	−15	−25	−26	−29	−38	−30	30	33
Income tax expense	0	0	0	0	0	0	0	0	0	0	0	0
Net income from continuing operations	−82	−11	−15	−14	−15	−25	−26	−29	−38	−30	30	33
Net income	−82	−11	−15	−14	−15	−25	−26	−29	−38	−30	30	33
EPS, basic	−$2.64	−$0.46	−$0.38	−$0.32	−$0.34	−$0.48	−$0.51	−$0.57	−$0.74	−$0.44	$0.43	$0.47
EPS, diluted	−$2.64	−$0.46	−$0.38	−$0.32	−$0.34	−$0.48	−$0.51	−$0.57	−$0.74	−$0.44	$0.43	$0.47
Weighted average shares, basic	31	23	39	44	45	51	51	51	51	67	70	70
Weighted average shares, diluted	31	23	39	44	45	51	51	51	51	67	70	70
EBITDA	−81	−10	−14	−13	−14	−24	−25	−28	−37	−29	−32	−34
Depreciation & amortization	0	0	0	0	0	0	0	0	0	0	0	0
EBIT	−81	−10	−14	−13	−15	−24	−25	−28	−38	−29	−32	−34